A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3037 participants.

Also called NCT02293395

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 3,037 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02293395
  • EudraCT 2014-004266-26
Other papers using this trial's data
  • Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial Lancet (London, England), 2017-05-06 DOI, PubMed 28325638
  • P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes JAMA cardiology, 2019-07-01 DOI, PubMed 31141104, PMC6547088 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, France, Hungary, Japan, Netherlands, Poland, Russia, South Korea, Spain, Sweden, Türkiye, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02293395. Randomized; double masking; primary purpose treatment. Start 2015-04-20 (actual); primary completion 2016-10-14 (actual). Results posted on 2017-11-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
Acronym
GEMINI ACS 1
Condition
Acute Coronary Syndrome
Intervention (Drug)
Acetylsalicylic acid
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Ticagrelor
Lead sponsor
Janssen Research & Development, LLC (class: industry)
Collaborator
Bayer (class: industry)
Collaborator
Duke Clinical Research Institute (class: other)
Collaborator
Harvard Medical School (HMS and HSDM) (class: other)

Record details

Record id
cardio:ct-nct02293395
Content hash
228be99d12622e4b245ce096f9d3d4ef6f827865ecb4c65afa68b7f40d13d67d